Today, MobileODT announced it has raised an additional $6.825 million in a Series B fundraising round led by OrbiMed Advisors - a leading healthcare venture fund. Previous investors Tristel plc. also participated in the round. MobileODT has raised over $13 million to date.
MobileODT plans to use the Series B funding to continue to expand its product portfolio and IP as well as grow sales and marketing efforts in the US and international markets in which it is currently selling.
Ariel Beery, CEO & Chairman of the Board said “We are excited to accelerate our growth through this financing round led by some of the world’s best strategic and healthcare investors. This financing together with the recent launch of the third generation mobile colposcope, the FDA cleared EVA System, will enable us to fulfill our promise to reach every patient.”
As a part of the new financing, Dr. Ron Ginor, a Venture Partner at OrbiMed Advisors, will join the MobileODT Board of Directors. Mr. Ariel Beery, the company’s co-founder and CEO will also serve as the Company’s Chairman of the Board and continue to lead MobileODT forward.
Ronny X. Ginor, MD, Venture Partner at OrbiMed Advisors commented: "MobileODT is at the forefront of a critical race to bring contemporary healthcare to the billions of people who do not have ready access to expert physicians. I believe their platform will impact and improve lives across the globe".
Paul Swinney, CEO of Tristel, added: “There are 5.8 billion people worldwide who have no access to healthcare that we would consider adequate. But, a great number of this population has access to a mobile phone. This is a new frontier in medicine that is developing rapidly. MobileODT is at the forefront of this exciting development in healthcare, and has had the foresight to acknowledge the importance of disinfection. We take great comfort in investing alongside the leading healthcare investor, Orbimed Advisors.”
MobileODT builds portable, smart, connected medical devices to enable health providers to reach every patient, everywhere. Their first product, the FDA cleared EVA System, is being used across 43 health systems in the United States, and by public and private providers in 26 countries around the world for cervical cancer screening and diagnosis, and forensic colposcopy for sexual assault examinations. The EVA System has been developed to serve as a practical solution to the challenges of resource limited healthcare: affordable and practical for the nurse or general practitioner at the point-of-care and point-of-treatment, and powerful enough to be used by expert clinicians as a replacement for their larger, more expensive devices, everywhere.
About OrbiMed Advisors
OrbiMed is a leading investment firm dedicated exclusively to the healthcare sector, with $14 billion in assets under management. OrbiMed invests globally across the spectrum of healthcare companies, from venture capital start-ups to large multinational companies utilizing a range of private equity funds, public equity funds, royalty/debt funds, and other investment vehicles. OrbiMed maintains offices in New York City, Herzliya, San Francisco, Shanghai, and Mumbai. As the largest investment firm dedicated to the healthcare sector globally, OrbiMed seeks to be a capital provider of choice. OrbiMed has the flexibility to provide equity and debt capital along with the global team resources required to be an exceptional long-term partner for building world-class healthcare companies.
Tristel is an infection prevention business which is unique in utilising the chemistry chlorine dioxide for the high-level disinfection of medical devices. The company operates in over 40 countries and is listed on the London Stock Exchange.
Since December 2016, Apollo Research and Innovation (ARI) has partnered with MobileODT to deploy the EVA System across South India.
In June 2017, Apollo ARI and MobileODT hosted our first community screening camp in Aragonda, a rural village in Tamil Nadu. The women learned of the health camp from community health workers, who engaged families in conversations on reproductive health, how to prevent cervical cancer, and who might be at risk.
The outreach is part of Apollo’s "Total Health Programme," India's first integrated rural healthcare service delivery network. Because being healthy requires many factors, community engagement and outreach services focus on nutrition, sanitation, education, reliable livelihood and income, infrastructure, clean water, and much more. Cervical cancer screening is just a part of the equation to ensure women are living happy, healthy lives, where they are empowered to know and make decisions for their own care. Simply put, Apollo is leading the way in India to deploy a community approach to improving health behaviors and outcomes, and increasing empowerment.
Together, With the EVA System, we are drastically expanding access to high quality screening, and ensuring no patient leaves the clinic, needing to continue to manage painful, uncomfortable, or life threatening conditions. To date, Apollo ARI and MobileODT have screened more than 500 women across South India, resulting in numerous cases of precancer, caught at an early stage, and saving countless lives.
**Name changed for patient privacy.
The EVA System now supports secure case sharing for providers. Healthcare providers can contact colleagues in real time, and collaborate to get feedback or a second opinion on cases. The platform allows providers to review patient history and annotated images and seamlessly discuss a patient case. The HIPAA compliant platform protects all patient information while allowing providers to support each case within a clinic, or across an ocean.
Here are some of the new features included in the third generation EVA System:
The EVA System is available for $3,600 today. Purchase here or contact us today at email@example.com
Resource limitations prevent most women globally from having access to reliable cervical cancer screening which, according to the World Health Organization, results in 270,000 deaths per year from the disease. But what if you could bring expert level diagnosis to every woman on earth?
The future of cervical cancer detection is efficient, mobile, and soon, predictive. Artificial Intelligence (AI) can recognize patterns invisible to the human eye and healthcare companies around the world are beginning to integrate machine learning into their solutions. At MobileODT, we are excited to join this AI revolution to save lives.
AI could change the course of diagnosing and treating cervical pre-cancer. Thanks to Intel’s Kaggle competition, we are addressing this issue and joining forces with data scientists around the world to improve outcomes.
Using images taken by MobileODT’s EVA System and classified by expert physician, Dr. Albert Singer, data scientists are competing to write the most accurate algorithm possible to detect cervix abnormalities and help guide treatment. For a woman in a hard to reach area, this has the potential to be life saving. The winning algorithm from the Kaggle competition will be integrated into the mobile application of the EVA System.
Watch Dr. Albert Singer describe the importance of determining cervix type:
Together we will continue to expand access to care so every woman, every where can have the same access to lifesaving care.
TechEmerge, a World Bank Initiative, pairs the EVA System with Leading Healthcare Provider in India - Apollo Hospitals
MobileODT is proud to announce its partnership with Apollo Hospitals -India’s leading healthcare provider and International Oncology– a speciality chain of cancer therapy centers, to apply MobileODT’s Enhanced Visual Assessment (EVA) System to increase access to low-cost, portable, and effective cervical cancer screening in India.
While cervical cancer is easily detectable and curable in its early stages for less than $28, only 3.1% of women in India are screened. Recent data indicates that there are approximately 132,000 new cases of cervical cancer and 74,000 deaths annually, accounting for ⅓ of all global cases of the disease.
The Apollo Hospitals group is Asia’s single largest integrated healthcare provider operating 70 hospitals, over 100 primary care diagnostic clinics, and more than 2,400 pharmacies across India. International Oncology provides screening and treatment for all cancers in several hospitals and outreach centers in India.
MobileODT and Apollo Research and Innovations (ARI), a division of Apollo Hospitals comprising of a comprehensive ecosystem are working together to undertake evaluation and validation of innovations in healthcare for women. Together we are leading a validation study across 5 rural and semi-urban locations to evaluate the benefits of integrating MobileODT’s EVA system for digital cervicography into Apollo Hospital’s primary screening for cervical cancer.
This partnership was made possible by the World Bank Group Initiative, TechEmerge, through the International Finance Corporation that matches technology companies around the world with partners in emerging markets to deliver tools that improve quality of life. MobileODT along with Apollo Hospitals Enterprise Limited and International Oncology were selected from 330 companies to apply our life-saving technology in diverse clinical settings. We believe this is the first of many opportunities to improve outcomes for every patient, across India.
We have some exciting news to share: as of December 19, 2016 the U.S. Food and Drug Administration approved our EVA (Enhanced Visual Assessment) System for marketing and sale in the United States!
The tragedy of cervical cancer - strongly addressed in major urban areas - still plagues much of America, where it is increasingly difficult for a woman to get a timely appointment with an expert gynecologist. Rural residents, specifically, disproportionately bear the burden of the 12,000 cases of cervical cancer each year. In part, this is because “approximately half (1,550, 49%) of the 3,143 U.S. counties lacked a singly ob-gyn, and 10.1 million women (8.2% of all women) lived in those predominantly rural counties.”*
The approval of the EVA System now enables colposcopists, rural health providers, and health providers in low resource settings across the country to benefit from the cost-effective, internet connected power of a robust video colposcope to serve every woman, everywhere.
If you’d like to learn how you can use the EVA System in the U.S. or anywhere else in the world, click here.
*Rayburn et. al. ”Distribution of American Congress of Obstetricians and Gynecologists Fellows and Junior Fellows in Practice in the United States” OBSTETRICS & GYNECOLOGY, VOL. 119, NO. 5, MAY 2012
FOR IMMEDIATE RELEASE:
[San Francisco, November 17, 2016]- MobileODT, a connected health company enabling health providers around the world to diagnose and address disease using its Enhanced Visual Assessment (EVA) System, is collaborating with Intel and Kaggle to harness the power of artificial intelligence to assist health workers to better manage the treatment of cervical cancer. The competition, hosted on Kaggle, will enable data scientists around the world to access thousands of cervical images to build algorithms that may assist in determining the eligibility criteria for treating pre-cancerous lesions with cryoablation. This project, beginning December 2016, builds on the work MobileODT has already begun in partnership with Global Good to harness the power of machine learning to improve cervical cancer screening outcomes.
Cervical cancer is the number one cause of cancer death for women in low resource settings, worldwide - a tragedy because cervical cancer takes 20 years to develop, and can be treated for less than $28 and in a single visit if caught in the first five years.
MobileODT currently holds a bank of tens of thousands of cervical images taken with their EVA System by health providers in over 21 countries, which will serve as a data set to be used by competition participants in their coding. This data set will allow for the building of algorithms that use image recognition to screen for precancerous lesions and potential risk for cervical cancer.
"Kaggle is excited to work with Intel and MobileODT on this challenge. It's a fabulous opportunity for our community to both push forward the cutting edge of image recognition while also solving an important public health problem." Anthony Goldbloom, CEO of Kaggle said.
The competition will consist of two stages: In stage one, reviewers will look at 4,000 patient cases classified under the guidance of Professor Albert Singer, a world leader in Colposcopy education and research, by cervical state eligibility for treatment. In stage two, reviewers will classify images of the cervix as low, medium or high risk for cervical pre-cancer. Kaggle’s competition platform will provide the framework for this project and consultation for the participants.
“The opportunity to collaborate with Intel and Kaggle and to open part of our data to developers looking to change the world through machine learning is extraordinary,” Ariel Beery, CEO of MobileODT, said. “We’re looking forward to seeing what comes from this competition in order to save as many lives as possible.”
Developers and data scientists interested in joining the competition can sign up to be notified about the launch here: https://software.intel.com/en-us/ai/competition-signup
For Intel's press release on this exciting project:
MobileODT- MobileODT is driven by a mission: to enable front line health providers in resource limited areas to deliver affordable and accessible visual based assessment and triage of diseases with connected medical devices. Their first product, The EVA System, functions on its own as an enhanced visual assessment screening or alongside any cervical cancer treatment. As a practical solution to the challenges of resource limited healthcare -- and to enable the extension of care into medium-resource settings -- the EVA System was built to be affordable and practical for the nurse or general practitioner at the point-of-care and point-of-treatment, everywhere.
Kaggle- Kaggle is the world's largest online data science community. With more than 700,000 active members across 194 countries, the Kaggle community competes to build the best solutions for solving complex data science problems. Kaggle users come from diverse educational backgrounds and are often experts in their fields. Working as individuals or in teams, the winning competitors are awarded prizes and industry recognition for their accomplishments. Kaggle competitions have tackled a wide range of problems hosted by commercial, government & research organizations, including diagnosing heart failure, identifying right whales, forecasting sales, and improving search relevance.
For press inquires contact:
We are excited to share with you that last week, at the UN General Assembly in New York, our CEO Ariel Beery had the privilege of presenting the EVA System in front of more than eighteen presidents, prime ministers, and foreign ministers from Africa and developing countries. It was an incredible opportunity to present to and collaborate with important leaders of countries where the incidence of cervical cancer is incredibly high.
The event was hosted by the Prime Minister of Israel, Benjamin Netanyahu and highlighted Israeli innovation in Africa and developing countries. Several Israeli companies changing the fields of health, agriculture, and education presented on their work in Africa.
This comes at an exciting time as, with the help of Rotary Club of Accra East, Ghana, we have just deployed our first devices in Ghana and have existing partnerships and devices in several other African countries including Ethiopia, Ivory Coast, Kenya, Rwanda, Ghana, The Gambia, and Mozambique. Together with local medical providers in Africa, we are working hard to lower the staggering number of women who are diagnosed with cervical cancer every year in developing countries.
Thanks to the Israel Mission to the UN, who included us in this event, we can continue to work with fantastic leaders to help improve access to high quality, affordable medical devices and health education in developing countries.
The EVA system can travel by car, plane, train...and now by boat! Recently, the Rotary Club of Accra East, led by Rotary President Ms. Gertrude Adzo Akpalu, delivered their donation of two EVA (Enhanced Visual Assessment) System mobile colposcopes to the Gynecology Department at Catholic Hospital in Battor, Ghana. The colposcopes were received by the Nurse Manager of the hospital, Mr. Philip Diame, who stood in for the hospital management team.
Cervical Cancer is the second most common cancer in women living in less developed regions. In 2012 there was an estimated 445,000 new cases which was 84% of the new cases worldwide*. This donation is another step towards lowering these numbers in underdeveloped countries and worldwide.
After the donation, North Tongu District Director of Health Services Mr. Evans Attivor, led the team across the Volta River. Head Gynecologist, Dr. Kofi Effah, led the clinical team in the screening using the EVA System in Dorfor Adidome, one of the remote communities in the North Tongu District.
The screening was immensely successful and users reported better magnification of the cervix, and the ability to share images with other experts. Women also appreciated being able to see images of their own cervix (#CervixSelfie). This is the first deployment of the EVA System in Ghana and its early success highlights the importance of pre cervical cancer screening in remote areas.
MobileODT is committed to reaching remote areas like Battor and Adidome in order to screen more women for cervical cancer. We want to thank Rotary Club of Accra East, Ms. Gertrude Adzo Akpalu, Mr. Philip Diame, Mr. Evans Attivor, and Dr. Kofi Effah for their fantastic work. We look forward to supporting more cervical cancer screening locations in Ghana with the EVA System.
*Human Papilomavirus (HPV) and Cervical Cancer, World Health Organization,
By Shoshana Kordova
Taking shots of your junk with your cellphone might seem inadvisable at best, but in the developing world, cervical selfies can save lives.
Cervical cancer is responsible for the deaths of more than 270,000 people annually, about 85 percent of whom live in low- or middle-income countries, and it is a leading cause of death in developing nations. Unlike many other medical conditions, though, cervical cancer is relatively easy to identify and treat. Researchers found that death rates from the disease the World Health Organization calls “one of the world’s deadliest—but most easily preventable—forms of cancer for women” decreased between 20 percent and 60 percent after women began to be screened for cervical cancer (PDF).
“There’s no reason a woman should die of cervical cancer just because of the fact that she’s not screened on time,” said Ariel Beery, the CEO and co-founder of Tel Aviv-based startup MobileODT, which makes and sells a small, easily portable, and relatively cheap version of a magnification instrument called a colposcope. “So what we do is make sure that woman gets screened on time.”
In the U.S., cervical cancer rates have been drastically reduced thanks to routine Pap smear screening, but that requires a health care infrastructure too often lacking in other parts of the world, particularly in rural areas. What are increasingly prevalent, on the other hand, are mobile phones, including smartphones: those small machines whose highly developed built-in imaging technology, in the form of cameras, has become so commonplace that most of us rarely think about the power we hold in our pockets and the outsize effect it can have around the world. MobileODT has sold more than 150 mobile colposcopes so far that integrate with smartphones to detect cervical cancer, for use in Kenya, Nicaragua, Haiti, and more than 15 other countries.
To read the Full Article click here.